drugset / Trial / NCT02228785

A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer

NCT02228785

Phase 2 Terminated 5 enrolled Cancer Advances Inc.
RandomizedOpen-labelTreatment

Summary

This study was designed to investigate the safety and tolerance of three doses (100µg, 200µg, 500µg) of G17DT for the treatment of patients with colorectal cancer.

Timeline

Start
1994-05
Primary completion
1994-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject G17DT Immunogen Vaccine 100 ug Intramuscular
Subject G17DT Immunogen Vaccine 200 ug Intramuscular
Subject G17DT Immunogen Vaccine 500 ug Intramuscular

Indications